NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Matthew Seavey, Ph.D., MBA, NightHawk’s Vice President of Research will be presenting data on PTX-35, and serving on an expert panel discussing modes of Treg activation, at the 4th Annual Treg Directed Therapies Summit (https://treg-directed-therapies.com/) being held on May 17-19th in Boston.
PTX-35 is a novel, potential first-in-class antibody immunomodulator of TNFRSF25 (death receptor 3), a receptor that is preferentially expressed by antigen-experienced T cells and can be utilized to expand regulatory T-cell subsets for auto/inflammatory indications. PTX-35 is the Company's first antibody-based product and is currently in a Phase 1 clinical trial for the treatment of patients with solid tumors.
Presentation Date/Time: Day-1, Wednesday, May 18th at 4:30 PM ET
Presentation Title: Agonizing Over Treg Expansion to Treat Human Disease: An Update on Our TNFRSF25-Agonist, PTX-35
Expert Panel Date/Time: Day-2, Thursday, May 19th at 11:30 AM ET
Expert Panel Title: Optimizing Routes of Administration & Delivery Mechanisms to Induce Timely Treg Specific Activation
- Describing a clinical-stage Treg immunomodulator with utility in both oncology and auto/inflammationp
- Demonstrating preclinical efficacy in several possible, clinical indications including transplantation, autoimmunity, and metabolic diseases
- Expanding plans for new indications and modalities, as well as opportunities for partnerships
NightHawk Biosciences, Inc.
NightHawk Biosciences is a fully integrated biopharmaceutical company focused on the development of new drugs from discovery through commercialization. The Company leverages its integrated ecosystem of subsidiaries to accelerate the development of novel therapies that arm the immune system, breaking through barriers that prolong traditional drug development. This empowers us to bring our ideas to life with efficient control, superior quality, and uncharacteristic agility.
For more information on the Company and is subsidiaries, please visit: https://www.nighthawkbio.com, and also follow us on Twitter.
Media and Investor Relations Contact
+1 919 289 4017
Spread the love. Be the first to like this post!
Metatron Releases All-in-One Artificial Intelligence Mobile Apps for iPhone and Android • MRNJ • Mar 27, 2023 9:00 AM
Memorandum of Understanding With Miranda Water Treatment Systems and Rainmaker Worldwide Inc. Extended • RAKR • Mar 27, 2023 8:50 AM
Hollywall Entertainment Inc., (OTC:HWAL) Announces the completion of its 2021 and 2020 Audit (s) • HWAL • Mar 24, 2023 12:48 PM
Glucose Health, Inc. Fiscal 2022 Annual Report • GLUC • Mar 23, 2023 3:23 PM
Nextech3D.ai Announces Its AI-Powered SaaS Platform Toggle3D Experiences A +963% Jump in Users in 60-Days Crossing Over 1000 Users • NTAR • Mar 23, 2023 7:07 AM
Lifecycle Assessment by Benchmark Shows TMC's NORI-D Nodule Project Could Outperform Land-Based Routes of Producing Nickel, Copper and Cobalt in Almost Every Impact Category Analyzed • TMC • Mar 22, 2023 1:44 PM